Candel Therapeutics, Inc. reveals strategy for advancing prostate cancer and glioma programs

Candel Therapeutics, Inc. reveals strategy for advancing prostate cancer and glioma programs
Candel Therapeutics shares oncology progress

Candel Therapeutics, Inc. announced that CEO Paul Peter Tak is presenting at the Stifel 2026 Virtual Targeted Oncology Forum.

The company is sharing new updates on its clinical pipeline with a particular focus on prostate cancer, non-small cell lung cancer (NSCLC), and recurrent glioma. This event provides investors and healthcare professionals an early look at Candel Therapeutics, Inc.'s current strategy and research progress as it works to advance therapies in the oncology sector.

Candel CEO Paul Peter Tak has previously called for stronger patient engagement to accelerate drug discovery at BioEquityEurope. The company’s leadership has also received recognition for regulatory excellence, as Chief Regulatory Officer Susan Stewart was named among RAPSorg 50 for 50. These developments reflect Candel Therapeutics’ focus on both patient-driven innovation and regulatory standards.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.
Weekly Top Bonuses
up to $2,500
deposit bonus for all clients
CLAIM BONUS
Your capital is at risk.